Zobrazeno 101 - 110
of 392
pro vyhledávání: '"35"'
Autor:
M Puglisi, Ignace Vergote, Qi Liu, Vanda Salutari, Robert M. Wenham, Stephanie Lheureux, Chyong-Huey Lai, Patricia Pautier, Stephen Michael Keefe, Antonio González-Martín, Radoslaw Madry, Paolo Zola, David Cibula, Jacob Korach, Samet Topuz, Jalid Sehouli, Kosei Hasegawa, Byoung-Gie Kim
Publikováno v:
Journal of Clinical Oncology. 37:TPS5603-TPS5603
TPS5603 Background: There is a significant unmet need to develop new regimens for BRCA1/2-nonmutated advanced ovarian cancer (OC). The PARP inhibitor olaparib is approved for women with platinum-sensitive, recurrent OC regardless of BRCA1/2 status an
Autor:
Denái R. Milton, Issa F. Khouri, Akash Mukherjee, Stefan O. Ciurea, Richard E. Champlin, Partow Kebriaei, Tapan M. Kadia, Farhad Ravandi, Marina Konopleva, Uday R. Popat, Rohtesh S. Mehta, Elias Jabbour, Jin Im, Alison M. Gulbis, Courtney D. DiNardo, Betul Oran, Hagop M. Kantarjian, Naval Daver
Publikováno v:
Journal of Clinical Oncology. 37:7047-7047
7047 Background: BCL-2 inhibitor Ven has shown a promising benefit in pts with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). There is paucity of information about the safety and efficacy of alloSCT post Ven. Methods: We conduct
Autor:
Rachel Ann Sanford, Artavazd Arumov, Patricia DeFusco, Leigh Ann Boyle, Ayca Gucalp, Marcia Edelweiss, Shanu Modi, Tiffany A. Traina, Sujata Patil, Nicholas Lamparella, Mila Gorsky
Publikováno v:
Journal of Clinical Oncology. 37:546-546
546 Background: A subset of TNBC is dependent on AR signaling. Enzalutamide (ENZA), an AR-antagonist, has activity in patients (pts) with metastatic AR+ TNBC, with a clinical benefit rate of 33%. This study tests the feasibility of adjuvant ENZA for
Autor:
Rene Costello, Amir Mortazavi, Joseph D. Schonhoft, Andrea B. Apolo, Lincy Chu, Primo N. Lara, Lisa M. Cordes, Sumanta K. Pal, Ryan Dittamore, Donald P. Bottaro, Christian Mayfield, Zishuo Ian Hu, Jane B. Trepel, Marissa Mallek, Carlos Diaz, Yipeng Wang, Mark N. Stein, Seth M. Steinberg, Amanda K. L. Anderson
Publikováno v:
Journal of Clinical Oncology. 37:4555-4555
4555 Background: CTCs may serve as biomarkers for clinical outcomes in GU tumor pts. We examined the association between baseline CTC enumeration, CTC heterogeneity, CTC morphologic subtypes, and progression-free-survival, overall survival and respon
Publikováno v:
Journal of Clinical Oncology. 37:e17016-e17016
e17016 Background: The aim of this study was to evaluate the efficacy and safety of paclitaxel/carboplatin as an adjuvant systemic chemotherapy for stage IB-IIA cervical adenocarcinoma patients after radical hysterectomy and pelvic lymphadenectomy wi
Autor:
Kazunori Saeki, Gerald Steven Falchook, Vivek Subbiah, Gary Maier, David S. Wages, Bhumika Prajapati, Timothy Madden, Shinji Hagiwara, Catherine Wheeler, Ruth Ann Subach, Mary Johansen, Filip Janku, Takeaki Suzuki, Milind Javle, Cassie Stone, Lindsay Bramwell, Shiraj Sen, Tracey Way, Shubham Pant
Publikováno v:
Journal of Clinical Oncology. 37:3008-3008
3008 Background: FF10502 is a synthetic pyrimidine nucleoside similar to gemcitabine (gem) with a sulfur in the pentose ring. FF10502 is a more potent inhibitor of DNA polymerase Beta than gem with activity in gem resistant patient (pt) derived xenog
Autor:
Lionel Duck, Gauthier Demolin, Lionel A. D'Hondt, Catherine Dopchie, Koenraad Hendrickx, Beatrice Lannoye, Fabienne Bastin, Dominique Lossignol, Oussama Ibrahim Hamdan, Willem Lybaert, Vincent Vandenhaute, Torkia Grira, Vincent De Ruyter, Karen Paula Geboes
Publikováno v:
Journal of Clinical Oncology. 37:4118-4118
4118 Background: Intestinal obstruction is a severe complication in patients (pts) with digestive or gynecological cancers. For inoperable pts, there is a need to relieve symptoms and limit nasogastric tube (NGT) use. Previous studies have suggested
Autor:
Brian E. Lewis, Neeraj Agarwal, Andrew W. Hahn, Leta Ko, Patrick Cotogno, Roberto Nussenzveig, Marcus Marie Moses, Elisa Ledet, Charlotte Manogue, Jodi Lyn Layton, Michael B. Lilly, Pedro C. Barata, A. Oliver Sartor
Publikováno v:
Journal of Clinical Oncology. 37:320-320
320 Background: Approximately 20-30% of men with metastatic castration-resistant prostate cancer (mCRPC) seem to respond to enzalutamide (ENZA) after prior exposure to abiraterone acetate and steroids (AA). The impact of genomic changes in androgen r
Autor:
Ola Bratt, Barry R. Davies, Nimish Shah, Krishna Narahari, Charles E. Massie, Henno Martin, Vincent Gnanapragasam, Ruth Tysoe, Mark Linch, Satish Kumar, Alex Freeman, Harveer Dev, Josephine Khan, Greg Shaw, Simon Pacey, Bihani Kularatne, Howard Kynaston, Anne Y. Warren
Publikováno v:
Journal of Clinical Oncology. 37:35-35
35 Background: Novel agents given prior to RP allows the study of drug effect(s) in primary human prostate cancer (PC), supporting future clinical study development. Pre-clinical and clinical data (mostly in setting of castration resistant PC) suppor
Autor:
Mark N. Stein, Tian Zhang, Carolyn Winters, Yuan Wu, Tina M. Mayer, W. Robert Lee, Julia Rasmussen, Bridget F. Koontz, Rhonda L. Bitting, Michael R. Harrison, Bart Frizzell, Sung Kim, Daniel J. George, Patrick Healy, Monika Anand, Rhonda Wilder, Andrew J. Armstrong, Colleen Riggan
Publikováno v:
Journal of Clinical Oncology. 37:29-29
29 Background: Salvage external beam radiotherapy (RT) and hormonal therapy improves survival over RT alone in men with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP). We investigated the safety/efficacy of enzal